CDKN2B downregulation and other genetic characteristics in T-acute lymphoblastic leukemia
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2092-6413
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
CDKN2B downregulation and other genetic characteristics in T-acute lymphoblastic leukemia ; volume:51 ; number:1 ; day:11 ; month:1 ; year:2019 ; pages:1-15 ; date:1.2019
Experimental & molecular medicine ; 51, Heft 1 (11.1.2019), 1-15, 1.2019
- Urheber
-
Jang, Woori
Park, Joonhong
Kwon, Ahlm
Choi, Hayoung
Kim, Jiyeon
Lee, Gun Dong
Han, Eunhee
Jekarl, Dong Wook
Chae, Hyojin
Han, Kyungja
Yoon, Jae-Ho
Lee, Seok
Chung, Nack-Gyun
Cho, Bin
Kim, Myungshin
Kim, Yonggoo
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1038/s12276-018-0195-x
- URN
-
urn:nbn:de:101:1-2019021421142555192475
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:44 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Jang, Woori
- Park, Joonhong
- Kwon, Ahlm
- Choi, Hayoung
- Kim, Jiyeon
- Lee, Gun Dong
- Han, Eunhee
- Jekarl, Dong Wook
- Chae, Hyojin
- Han, Kyungja
- Yoon, Jae-Ho
- Lee, Seok
- Chung, Nack-Gyun
- Cho, Bin
- Kim, Myungshin
- Kim, Yonggoo
- SpringerLink (Online service)
Ähnliche Objekte (12)
FoxO3a Gene Down-regulation in Pathogenesis of Pediatric Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia
Relapsed Acute Lymphoblastic Leukemia
Cardiac manifestation of acute lymphoblastic leukemia
Acute lymphoblastic leukemia simulating breast carcinoma
Precision medicine in acute lymphoblastic leukemia
Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia
Prognostic impact of leukemia biology in pediatric acute lymphoblastic leukemia
Minimal Residual Disease in Acute Lymphoblastic Leukemia
Targeting chemokines for acute lymphoblastic leukemia therapy
Acute Lymphoblastic Leukemia Presenting as Fanconi Syndrome
Th1 cytokines in pediatric acute lymphoblastic leukemia
FoxO3a Gene Down-regulation in Pathogenesis of Pediatric Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia
Relapsed Acute Lymphoblastic Leukemia
Cardiac manifestation of acute lymphoblastic leukemia
Acute lymphoblastic leukemia simulating breast carcinoma
Precision medicine in acute lymphoblastic leukemia
Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia
Prognostic impact of leukemia biology in pediatric acute lymphoblastic leukemia
Minimal Residual Disease in Acute Lymphoblastic Leukemia
Targeting chemokines for acute lymphoblastic leukemia therapy
Acute Lymphoblastic Leukemia Presenting as Fanconi Syndrome
Th1 cytokines in pediatric acute lymphoblastic leukemia
FoxO3a Gene Down-regulation in Pathogenesis of Pediatric Acute Lymphoblastic Leukemia
Acute lymphoblastic leukemia
Relapsed Acute Lymphoblastic Leukemia
Cardiac manifestation of acute lymphoblastic leukemia
Acute lymphoblastic leukemia simulating breast carcinoma
Precision medicine in acute lymphoblastic leukemia
Synergism between the mTOR inhibitor rapamycin and FAK down-regulation in the treatment of acute lymphoblastic leukemia
Prognostic impact of leukemia biology in pediatric acute lymphoblastic leukemia
Minimal Residual Disease in Acute Lymphoblastic Leukemia
Targeting chemokines for acute lymphoblastic leukemia therapy
Acute Lymphoblastic Leukemia Presenting as Fanconi Syndrome